Home Biosimilar Antibodies Immunology & Inflammation Interleukins antibody Nidanilimab (Anti-IL-1RAP / IL-1R3) For research use only.
Not for use in humans.

Nidanilimab (Anti-IL-1RAP / IL-1R3)

Synonyms: CAN04

Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD.

Nidanilimab (Anti-IL-1RAP / IL-1R3)

Selleck's Nidanilimab (Anti-IL-1RAP / IL-1R3) has been cited by 2 publications

Purity & Quality Control

Batch: A244401 Purity: 99% Protein concentration: 4.52mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective Interleukins Inhibitors

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 0
JTE-607 Dihydrochloride 0 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 3 PIKfyve
MD2-TLR4-IN-1 0 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 59 TLR4,NO,TNF-α
Apilimod 15 PIKfyve
LMT-28 0
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 4
Diethyl phosphate 0
RCM-1 3 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 1 iNOS,TNF-α,PGE2
PKR-IN-C16 6 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 0 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 20 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 0 TNFα,MCP-1/CCL2,NOX2
AUDA 0 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 1 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 0 MPO
Muscone 3 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 13
Methylthiouracil 0 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD.

Product Details

CAS No. 2171061-85-9
Molecular Weight 143.56 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Nidanilimab (Anti-IL-1RAP / IL-1R3) | Nidanilimab (Anti-IL-1RAP / IL-1R3) supplier | purchase Nidanilimab (Anti-IL-1RAP / IL-1R3) | Nidanilimab (Anti-IL-1RAP / IL-1R3) cost | Nidanilimab (Anti-IL-1RAP / IL-1R3) manufacturer | order Nidanilimab (Anti-IL-1RAP / IL-1R3) | Nidanilimab (Anti-IL-1RAP / IL-1R3) distributor